Dengue Envelope-1 32kDa
Description
Product Specs
Purified by proprietary chromatographic technique.
Product Science Overview
The Dengue Virus (DENV) is a mosquito-borne virus that causes dengue fever, a disease that affects millions of people worldwide. There are four distinct serotypes of the dengue virus (DV1–4), each with similar genome sequences and envelope protein (E protein) antigenic properties . Among these, Dengue Virus Subtype 1 (DV1) is often predominant in infections.
The envelope (E) glycoprotein of the dengue virus plays a crucial role in the virus’s life cycle. It mediates the attachment of the virion to the host cell receptor and facilitates the fusion of the virus envelope with the target cell membrane . The E protein is also a major target for neutralizing antibodies, making it a key focus for vaccine development and diagnostic assays.
The recombinant DV1 E protein, specifically the 32kDa variant, is produced using various expression systems, including bacterial, yeast, and mammalian cells. This recombinant protein is used in research and diagnostic applications to study the immune response to dengue virus and to develop vaccines and therapeutic antibodies .
- Diagnostic Assays: The recombinant E protein can be used in diagnostic assays to detect primary or secondary dengue infections. This is particularly important for early diagnosis and treatment, which can prevent severe complications such as dengue hemorrhagic fever .
- Vaccine Development: The E protein is a major component of several experimental dengue vaccines. By eliciting a strong immune response, these vaccines aim to provide protection against all four serotypes of the dengue virus .
- Therapeutic Antibodies: Monoclonal antibodies targeting the E protein have shown promise in neutralizing the virus and preventing infection. These antibodies can be used as a treatment option for dengue virus infections .
